Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
| Autor: | Tsutomu Furuse, Kenji Hashimoto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class lcsh:RC435-571 Serotonin reuptake inhibitor medicine.medical_treatment Atypical antipsychotic Tricyclic antidepressant Fluvoxamine Psychotic depression medicine.disease Psychiatry and Mental health lcsh:Psychiatry Case report medicine Major depressive disorder Antidepressant Psychology Psychiatry Antipsychotic medicine.drug |
| Zdroj: | Annals of General Psychiatry, Vol 8, Iss 1, p 26 (2009) Annals of General Psychiatry |
| Popis: | Background Psychotic depression is a clinical subtype of major depressive disorder. A number of clinical studies have demonstrated the efficacy of the combination of an antidepressant (for example, a tricyclic antidepressant or selective serotonin reuptake inhibitor (SSRI)) and an atypical antipsychotic or electroconvulsive therapy in treating psychotic depression. In some cases, the clinician or patient may prefer to avoid antipsychotic drugs altogether because of the risk of extrapyramidal side effects (EPS) in patients with psychotic depression treated with these drugs. Methods We report five cases where fluvoxamine monotherapy was effective in the patients with psychotic depression. Results The scores on the Hamilton Depression (HAM-D) scale and the Brief Psychiatric Rating Scale (BPRS) in the five patients with psychotic depression were reduced after fluvoxamine monotherapy. Conclusion Doctors should consider fluvoxamine monotherapy as an alternative approach in treating psychotic depression because it avoids the risk of EPS from antipsychotic drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|